Eikonoklastes Therapeutics
Cincinnati, US · 2 known investors
Find your way into Eikonoklastes Therapeutics
Sign up to see every warm intro you have to Eikonoklastes Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eikonoklastes Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
BH

Bruce HalprynExecutive
Board
SL
KM

TF
Thomas FinnBoard director
JN
Joseph NolanBoard director
RJ
Robert JohnsonBoard director
Investors · 2
CincyTechlisted by CincyTechCincinnati · $500K – $750K
How we know: CincyTech's portfolio page · board seat on SEC Form D · funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$25M disclosed across 6 of 7 rounds · 2020–2025
▶$16.1MraisedOct 2026 · 15 investors · PharmaceuticalsRule 506(b)
▶$16.1MraisedOct 2026 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bruce HalprynExecutive Officer, Director
- Samuel LeeExecutive Officer, Director
- Kenneth MorandDirector
- Thomas FinnDirector
- Robert JohnsonDirector
- Joseph NolanDirector
- Offering amount
- $18.6M
- Amount sold
- $16.1M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedJun 2024 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedJun 2024 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas FinnDirector
- Neel PatelDirector
- Meyer FrucherDirector
- Kenneth MorandDirector
- Bruce HalprynExecutive Officer, Director
- Samuel LeeExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $2.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2MraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Samuel LeeExecutive Officer, Director
- Neel PatelDirector
- Bruce HalprynExecutive Officer, Director
- Thomas FinnDirector
- Kenneth MorandDirector
- Meyer FrucherDirector
- Offering amount
- $15M
- Amount sold
- $2M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2.8MraisedJan 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedJan 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bruce HalprynExecutive Officer, Director
- Kenneth MorandDirector
- Thomas FinnDirector
- Samuel LeeExecutive Officer, Director
- Neel PatelDirector
- Offering amount
- $7M
- Amount sold
- $2.8M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3.2MraisedMay 2021 · 9 investors · PharmaceuticalsRule 506(b)
▶$3.2MraisedMay 2021 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bruce HalprynExecutive Officer, Director, Promoter
- Thomas FinnDirector
- Samuel LeeExecutive Officer, Director
- Neel PatelDirector
- Kenneth MorandDirector
- Offering amount
- $7M
- Amount sold
- $3.2M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.1MraisedMar 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedMar 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- SAMUEL LEEExecutive Officer, Director, Promoter
- BRUCE HALPRYNExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $1.1M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Eikonoklastes Therapeutics's investors?
- Eikonoklastes Therapeutics's investors include CincyTech, JobsOhio Ventures.
- How much funding has Eikonoklastes Therapeutics raised?
- Eikonoklastes Therapeutics has disclosed $25M raised across 6 of its 7 known rounds.
- Where is Eikonoklastes Therapeutics headquartered?
- Eikonoklastes Therapeutics is headquartered in Cincinnati, US.
